The Syneos Health Podcast

One of the biggest trends making headlines and impacting the healthcare industry to date is the rising popularity of GLP-1 drugs. Initially developed for diabetes management, these products have recently gained traction for weight loss indications. But with promising efficacy and growing popularity, is the healthcare industry truly prepared for the challenges posed by these drugs becoming such a hot commodity in the market?Tom Albers, Vice President of Strategy at Syneos Health company Spherico, joins the podcast to discuss his insights on the future of weight loss drugs – payer challenges, the transformative potential of these drugs, and the need for smart investments in data and evidence.For more content on value and access, check out these insights: MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key AccountsSyneos Health Podcast: The Inflation Reduction ActBuilding a Market Access Case for Real World Evidence in OncologyThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Syneos Health Podcast, we embark on a journey into the metaverse – a revolutionary concept that's transforming the way we approach training and learning. As we delve into the world of the metaverse and its implications for healthcare training, Michael Shim, PharmD, National Director, Field Medical Affairs and Marie Latsa, PharmD, Community Medical Director at Syneos Health, will share their firsthand experiences with metaverse-based training for Medical Science Liaisons (MSLs), and provide valuable insights into the current state and future potential of this cutting-edge technology that offers an immersive and efficient training alternative.Join us on this exciting journey into the metaverse and discover its role in shaping the future of education and training in healthcare.For more of our insights on MSLs and Medical Affairs, check out these pieces on our Insights Hub:A Field MSL Perspective on Tech-Enablement Using the MetaverseLeveraging Metaverse Capabilities for Medical AffairsMedical Science Liaisons: Your Role in Creating a Culture of ExcellenceEarly Adoption of Metaverse Technology in Medical AffairsUsing Omnichannel to Drive Integration between Medical and CommercialEngaging Patient Communities: The Changing Role of Medical AffairsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The emergency department (ER) can be a place of chaos, panic and infinite amounts of unpredictability. Not knowing what can come through the doors at any given time makes this environment impossible to foresee and prepare for.  Because of this uncertainty, the ER (and its patients) can be a particularly challenging target for clinical trials.  In this episode, Dr. Ruth Henrice-Desrosiers, Medical Director, Syneos Health joins the podcast to discuss critical aspects to be considered by biopharma companies when choosing to bring a clinical trial to the ER—from location and cost implications to informed consent challenges, and everything in between.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. But with a multitude of new challenges facing this industry come multifold new opportunities for value creation and chances to reach new heights. In this episode, Lee Taurman, Global Head of Syneos One and Keith Ruark, SVP Strategic Business Development, Syneos Health are joined by Ali Pashazadeh and Max Baumann, Co-Founders of Treehill Partners, to discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.  learn strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What is the healthcare industry up against in terms of recruiting, hiring, and retention, in the increasingly competitive job markets of China, Korea and Japan? Leigh Householder and Sam Wilson, commercial solutions lead for APAC, Syneos Health,  discuss how changing customer needs, evolving market dynamics and shifts in customer engagement  continue to be  challenges when recruiting top talent in the region.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field Force Trend Talks: The Data EffectThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In our previous episode, we covered how companies can harness the power of digital therapeutics to improve their brand’s value proposition. But what does it really take to get a clinically validated prescription digital product to market? Dr. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics joins us on the second episode of our two-part series on digital therapeutics to discuss the diligence required to help regulators, health plans and payers, clinicians, and patients understand the potential of these digital solutions outside of entertainment—and how to apply the principles of traditional, biopharmaceutical types of drug development, validation and regulatory exercises to get them into the hands of patients. Listen to part one of our conversation on digital therapeutics with Austin Speier, Chief Strategy Officer of Click Therapeutics, here.  And for a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Digital therapeutics (DTx) are projected to be $50 billion industry by 2025. While many minds may immediately jump to unregulated companion apps when they hear “digital,” there are also clinically validated prescription digital products that act complementary to or in combination with traditional biopharmaceutical therapies. As these prescription DTx gain traction, how can companies harness their power to improve their brand’s value proposition? In this first of two episodes on DTx, Michael Sarshad, Managing Director, Commercial Advisory at Syneos Health and Austin Speier, Chief Strategy Officer, Click Therapeutics, join the podcast to discuss the growing market and opportunities for DTx across the product lifecycle, where DTx can add value and ways to think about how to integrate them into a brand strategy. For a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

"It's July 2022. This morning I tried to donate my kidney, this afternoon the transplant team told me that I can't, I have cancer." Words no one wants to hear. Even for a former Jeopardy! champion with degrees in molecular biology and two decades of experience in the biopharma industry, the implications of the phrase are overwhelming.Nearly a year later, our flagship podcast host Jeff Stewart is telling his story.Today, Nick Kenny, Chief Scientific Officer at Syneos Health, turns the tables on Jeff, interviewing him on his recent experience being diagnosed and undergoing treatment for two separate cancers. They discuss the realities today for patients like Jeff who are dealing with complex cancer diagnoses—including information overload both fake and real, and the importance of “pre-bunking”—and his newly released book, Living: Inspiration from a Father with Cancer.At a time when regulators in our industry at large are increasingly and rightly focused on patient perspectives in drug development, and with ASCO, the single largest global gathering of about 50,000 clinical cancer experts right around the corner in early June, this is a very timely discussion.Read excerpts of the book on NPR.Check out our other content on the patient experience:Webinar: Patient Perspectives as Essential in Next-Generation Clinical TrialsExploring the Value and Impact of Patient-Reported Outcomes in Patient-Centric CAR-T Clinical Trials3 Ways Patient Voice is Impacting Rare Disease Research, According to AdvocatesThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

How can we use technology and increasing volumes of data to change the future of human health and healthcare as we move forward into 2023 and beyond? In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Bob Zambon, VP, Solution Architecture Group, Syneos Health, to discuss how increasing numbers of varying health data − medical data, clinical data, interaction data, program data – will affect a vastly privacy forward industry.Listen to the podcast to find out how data will impact the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field ForceFind more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

How will a new field for the field force keep the doors open for customer communication while considering differences in culture, therapy, product lifecycle stage and healthcare professional preference?In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Ewan Cuthbertson, SVP, European Deployment Solutions, Syneos Health, to discuss how the field force is reemerging after a global pandemic and how it will impact the healthcare industry.Listen to the podcast to find out what a new field for the field force means for the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeFind more of our content on Digital Medicine and MedTech topics. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

How will Digital transformation continue to impact the healthcare industry and help drive automation, efficiencies, quality and other changes to how we engage and operate in the future?In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Skye Hodson, PhD, Senior Director, Product Solutions & Asset Team, Syneos One, to discuss how various aspects of digital transformation continue to impact the healthcare industry.Listen to the podcast to find out what the future holds for healthcare and digital transformation. Learn more about 2023 Health Trends here.More Episodes int he 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for Purpose Find more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Last year the FDA approved the first gene therapy for hemophilia B. This year, the first gene therapy may be approved in the US for hemophilia A. What does the gene therapy revolution mean for patients, payers, and pharma? Ankita Chowdhury, Senior Engagement Manager, Commercial Advisory at Syneos Health®, joins the podcast to discuss the landscape of recent hemophilia gene therapy approvals, the state of upcoming additional therapies to market, and key considerations for developers to address in order to optimize access, pricing and reimbursement for patients impacted by this rare disease. For more of our insights on rare disease and gene therapies, check out:The Importance of the Right Go-to-Market in Cell Therapy CommercializationWEBINAR: Early Integrated Evidence Strategy for Cell & Gene TherapiesExploring an Expedited Regulatory Pathway for Cell and Gene TherapiesSuccess Factors for Commercializing Cell and Gene TherapiesSyneos Health Podcast: The Value of Registries NOTE: At the time of recording, Biomarin’s hemophilia A product was expected to receive FDA approval in March of this year. Since then, news broke that FDA review will be delayed until June.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies?Dennis Kim, Senior Engagement Manager and Em Coriale, Director in the Value & Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.   For additional insights on the Inflation Reduction Act from our Reputation & Risk Management team, visit our blog.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

How will Artificial Intelligence continue to impact the healthcare industry and its potential to introduce new technologies, enabling a shift from promise to performance?  In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Andrew Barron, SVP of Global Site Start Up & Regulatory, to discuss. Listen to the podcast here or watch the video to find out what they are thinking about ChatGPT, the next industrial revolution and more.Learn more about 2023 Health Trends here. And be sure to check out Leigh’s kick-off episode of the podcast series, as well as her recent interview with patient advocate James Ian.Find more of our content on site and patient engagement and regulatory topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

 In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with James Ian , a Musician and Actor who lives with Spinal Muscular Atrophy Type Three—a rare neuromuscular disease that attacks the neurons that control all the voluntary muscles in the body. James is a passionate advocate for disability inclusion, particularly in the arts and entertainment industry, and here they discuss representation of disabilities through authentic, intentional and purpose-driven advocacy in media and technology.  Listen to the podcast here or watch the video to learn what’s changed, what’s changing and what matters most right now. Learn more about 2023 Health Trends here. And be sure to check out Leigh’s kick-off episode of the podcast series (November 29—2023 Health Trends: Personally, Purposefully Building What’s Next).Find more of our content on rare disease and patient voice topics. Follow James Ian on Instagram @jamesianmusic  Leigh Householder is the EVP/Managing Director, Technology & Data at Syneos Health.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

This new podcast mini-series features interviews with industry leaders, focusing on hot topics within Regulatory Operations (Reg Ops).Reg Ops is evolving in response to a rapidly changing regulatory landscape as well as the industry’s focus on achieving operational efficiency and excellence. Technological innovations such as advancements in Regulatory Information Management (RIM) capabilities are accelerating Reg Ops in their transition from traditional operational roles to more strategically focused roles, including a shift toward Delivery Excellence. Organizations must adapt to the evolution of Reg Ops, including rethinking their approach to attracting and retaining talent, to remain competitive and at the forefront of innovation.In this episode, Reg Ops Edition host Caroline Masterman-Smith is joined by Matt Neal, Senior Director, Global Regulatory Affairs Operations at Atara Biotherapeutics; Stuart Goodall, Vice President of Regulatory Services Delivery at Syneos Health; and Hannah Riley, Engagement Manager within R&D Advisory at Syneos Health to discuss how the regulatory world has moved from truckloads of paper to electronic processes; how that, in turn, has changed the skillsets required for the Reg Ops function; and how companies need to think and act differently in order to attract and retain the talent they need.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  Be sure to read the white paper discussed in this episode: Attracting and Retaining Talent in the Age of Evolution for Regulatory OperationsIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

It’s a volatile time for biopharma, and a unique juncture in our industry’s history. War in Ukraine, a bearish market and supply chain chaos are just a few of the factors that kept much of the industry away from the table. Entering 2023, the investment and dealmaking panorama remains a puzzle. Despite worries and uncertainties, there are hints that dealmaking intensity may be poised for a rebound after a year of inertia that mirrored the slump in major biotech stock indexes. What lies ahead for dealmaking in the biopharmaceutical industry in 2023?Our 13th Dealmakers’ Intentions Survey attempts to answer this question, based on responses from more than 100 members of the biopharma community, most of them with executive-level influence on decision-making. This report, released recently at Biotech Showcase—an event co-located with the famous J.P. Morgan Healthcare Conference in San Francisco—captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking. Neel Patel, Executive Managing Director, Commercial Advisory Group at Syneos Health and lead author of the report, joins the podcast to discuss the industry’s first time back in person at J.P. Morgan in three years, as well as key findings from the survey.Read the latest Dealmakers’ Intentions report here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What’s Changed, What’s Changing and What Matters Most Right NowIn this inaugural episode of the limited podcast series on 2023 Health Trends, we’re setting the stage with Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, Leigh Householder. Leigh provides a high-level look at what will be different this year. First, she discusses urgent optimism and the personal, purposeful commitments we have; to take our industry and our world to next. She goes through 12 Health Trends spanning technology, healthcare advancement and human engagement. These trends help us imagine what could be; our next – the future. Listen and learn what’s changed, what’s changing and what matters most right now.Learn more about 2023 Health Trends here. Leigh Householder is the EVP/Managing Director, Technology & Data Science at Syneos Health. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!   We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

When it comes to the generation and use of real-world data (RWD), there are variable and evolving stakeholder needs. Put it in the context of a rare disease, where patient samples are decreasing as diseases splinter with increasing specificity in diagnosis, and the prospect of meeting these stakeholder needs becomes more daunting. Layer on special circumstances—like a required 15 years of post-approval follow-up data for cell and gene therapies (CGT)—and the cards seem to be stacked against you. One way companies can alleviate the burden of RWD generation is through patient registries.Mike D’Ambrosio, VP, Head of Real World Evidence Solutions, Susan Goodlow, VP, RWE and Late Phase Operations and Ray Huml, Head of the Rare Disease Consortium at Syneos Health, discuss the importance of registries for clinical research—particularly for rare disease and CGT, the evolution of rare disease registries and opportunities for the future, and how we can unlock the value of RWD generated from rare disease registries, for all stakeholders.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. Visit our Insights Hub for other content on RWE, rare diseases, and cell and gene therapy.For more episodes on these topics, try:Opportunities and Challenges in Cell and Gene TherapyNavigating the Rare Disease LandscapeReal World Evidence and Rare Diseases, Part 1Real World Evidence and Rare Diseases, Part 2 If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits—and this is especially true for small or emerging biotechs with limited shots on goal.  But by separating fact from fiction and understanding how to identify fit for purpose solutions, these companies can lay the roadmap for successful implementation of a decentralized clinical trial (DCT) strategy. Stephanie Gonzalez, Senior Vice President and Head of Global Biotech Solutions at Syneos Health and Alison Holland, Executive General Manager for Decentralized Clinical Trials at Medable debunk some common myths and provide an overview of the benefits decentralization can bring to biotechs.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. For more on DCT strategy, check out these insights:3 Capabilities to Achieve Optimal Blend of On-Site and Virtual Patient Engagement in DCTsNot All Decentralized Clinical Trial Capabilities Are Created Equal4 Ways Decentralized Clinical Trials Can Be Game Changers for Better Patient OutcomesHybrid Decentralized Trials in Oncology: A Path to DiversityIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.